Does Rallies show 13F holders for INDV?

Yes. Rallies tracks hedge fund and 13F ownership data for INDV, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INDV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INDV. It does not provide personalized investment advice.

INDV (Indivior Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Indivior Pharmaceuticals, Inc. Common Stock (INDV) is a publicly traded Healthcare sector company. As of May 20, 2026, INDV trades at $38.04 with a market cap of $4.32B and a P/E ratio of 22.16. INDV moved +2.91% today. Year to date, INDV is +3.53%; over the trailing twelve months it is +216.69%. Its 52-week range spans $7.33 to $41.00. Analyst consensus is strong buy with an average price target of $50.67. Rallies surfaces INDV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INDV stock?

Hedge funds tracked by Rallies that own INDV include Oaktree Capital, Mangrove Partners, Soros Fund, Rokos Capital, and Centerbook Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Indivior Pharmaceuticals, Inc. Common Stock.

INDV Key Metrics

Key financial metrics for INDV
Metric	Value
Price	$38.04
Market Cap	$4.32B
P/E Ratio	22.16
EPS	$1.68
Dividend Yield	0.00%
52-Week High	$41.00
52-Week Low	$7.33
Volume	1.02M
Avg Volume	0
Revenue (TTM)	$1.24B
Net Income	$210.00M
Gross Margin	80.23%

Top Hedge Funds Holding INDV

Oaktree Capital holds 7.11M shares of INDV, changed -97.24% as of Dec 31, 2025.
Mangrove Partners holds 2.74M shares of INDV, changed -0.13% as of Mar 31, 2026.
Soros Fund holds 1.15M shares of INDV, changed -14.73% as of Dec 31, 2025.
Rokos Capital holds 500.03K shares of INDV, changed +0.00% as of Dec 31, 2024.
Centerbook Partners holds 48.50K shares of INDV, changed -28.76% as of Mar 31, 2026.

Latest INDV News

Monthly Injectable Buprenorphine Linked to 3.5–8.1x Lower Relapse Risk and 62% Fewer Infections — May 20, 2026
Indivior launches $175M accelerated share repurchase, initial 3.7M shares delivered — May 4, 2026
Indivior Q1 Revenue Jumps 19%, SUBLOCADE Sales Climb 32%, Raises 2026 Guidance — Apr 30, 2026
Indivior Model Projects 747 Staff Hour Cuts and $22,148 Monthly Savings in Prisons — Mar 31, 2026
Indivior Prices $450M 0.625% Convertible Notes to Repay Debt, Buy Shares — Mar 13, 2026

Recent INDV Insider Trades

Ryan Barbara bought 8 (~$248.68) on Mar 13, 2026.
Ryan Barbara bought 31 (~$1.01K) on Mar 9, 2026.
Kingsley Stuart A bought 940 (~$29.95K) on Mar 6, 2026.

INDV Analyst Consensus

4 analysts cover INDV: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.67.

Common questions about INDV

Who owns INDV stock?: Hedge funds tracked by Rallies that own INDV include Oaktree Capital, Mangrove Partners, Soros Fund, Rokos Capital, and Centerbook Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Indivior Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for INDV?: Yes. Rallies tracks hedge fund and 13F ownership data for INDV, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INDV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INDV. It does not provide personalized investment advice.